Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+urothelial+carcinoma

3 Results

Sort By:

Non-invasive Urinary Biomarker for the Detection of Bladder Urothelial Carcinoma

Unmet NeedBladder cancer is fifth most common cancer in the US and tenth most common cancer worldwide. In the US, over 80,000 new cases will be diagnosed and approximately 17,000 will die from the disease in 2018. Bladder cancer is diagnosed via the use of cystoscopy. However, this procedure is considered too costly and invasive to be utilized in routine...

Published: 7/4/2024 | Inventor(s): Mohammad Hoque, Akira Oki

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Oncology > Urothelial Carcinoma

Engulfment Gene GULP1 as a Functional Tumor Suppressor in Urothelial Carcinoma

Invention Novelty:The technology identifies a novel biomarker to detect the presence of bladder cancer via a urine test. The technology could be coupled with existing urine-based cancer tests to improve sensitivity as a diagnostic or to test drug efficacy. Value Proposition:Bladder cancer (BC) is the 6th most common cancer in the US, with approximately...

Published: 7/4/2024 | Inventor(s): Mohammad Hoque, Masamichi Hayashi, Elisa Guida

Keywords(s): Biomarker, Bladder Cancer, Cancers, Disease Indication, Epigenetic, Methylation, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics, Urothelial Carcinoma

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Bladder Cancer, Clinical and Disease Specializations > Oncology > Urothelial Carcinoma, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Urology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS

UNMET NEEDChronic environmental exposure induces cancer stem cells (CSCs) with SOX2 overexpression, one of the most important CSC factor for urothelial cancer (UC). COX2 and YAP1 coordinately regulate SOX2 expression, and mutually compensate for the reduction of expression of SOX2 to maintain CSCs. Thus targeting the COX2/YAP/SOX2 signaling axis eliminates...

Published: 7/4/2024 | Inventor(s): Mohammad Hoque, David Sidransky, Akira Oki

Keywords(s): Antagonists/Inhibitors, Bladder Cancer, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Urothelial Carcinoma

Category(s): Clinical and Disease Specializations > Oncology > Bladder Cancer, Clinical and Disease Specializations > Oncology > Urothelial Carcinoma, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Urology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets